Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Peter Schmid, Cynthia X. Ma, Yeon Hee Park, Simon Lord et autres
PURPOSE: Triple-negative breast cancer (TNBC) is a heterogeneous disease with high recurrence rates and poor prognosis, often requiring multiple therapies. BEGONIA was a phase Ib/II, multiarm, platform study evaluating the safety and efficacy of first-line treatment combinations with durvalumab (anti-PD-L1 antibody) for …
gb, us, kr, tw, ca, pl, sg (code pays fourni par la source)
0 citations
Clinical Cancer Research